VivoSim Labs
Tracked across 4 events · 25 articles · First seen Jun 29, 2026 · Last active Aug 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: VivoSim Labs announced data demonstrating the high predictive power of its AI-enabled NAMkind Liver and NAMkind GI platforms for preclinical safety testing, which is expected to increase demand for its services and improve its market position.
Jun 29, 2026 · 7 articles
Business
Impact: VivoSim Labs is the issuer of the private placement, raising $4 million for working capital. The offering includes shares and warrants at $0.85 per share, with existing warrants amended to the same price.
Jul 16, 2026 · 6 articles
Business
Impact: VivoSim achieved its first commercial sales in China, validating its channel strategy and opening a significant new market. The company expects China to become a meaningful revenue contributor.
Jul 21, 2026 · 6 articles
Regulatory
Impact: VivoSim regained Nasdaq compliance, received milestone payments, and completed financing, boosting its cash position and reducing delisting risk.
Aug 06, 2026 · 6 articles
ERGEN INTELLIGENCE
Track VivoSim Labs live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard